Related Experiment Video

Updated: Aug 9, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?

I Irwin, J W Langston

    Life Sciences
    |January 21, 1985
    PubMed

    Insights

    The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is converted to MPP+, which accumulates in the substantia nigra. This selective accumulation of MPP+ may explain MPTP

    Area of Science:

    • Neuroscience
    • Toxicology

    Background:

    • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin.
    • MPTP is metabolized to 1-methyl-4-phenylpyridinium (MPP+).

    Purpose of the Study:

    • To investigate the distribution and metabolism of MPTP and its metabolite MPP+ in the squirrel monkey brain.
    • To explore the relationship between MPP+ accumulation and the selective neurotoxicity of MPTP.

    Main Methods:

    • Administration of MPTP to squirrel monkeys.
    • Measurement of MPTP and MPP+ concentrations in various CNS tissues over time.
    • Use of monoamine oxidase (MAO) inhibitor pargyline to block MPTP biotransformation.

    Main Results:

    • MPP+ concentration increased in the substantia nigra within 72 hours, reaching the highest levels compared to other CNS tissues.
    • MPP+ showed time-dependent elimination in other brain areas.
    • Pargyline pretreatment blocked MPTP neurotoxicity and biotransformation, altering MPTP distribution.
    • MPTP levels decreased rapidly in most regions except the substantia nigra and eye when pargyline was administered.

    Conclusions:

    • The selective neurotoxicity of MPTP may be linked to the accumulation of its metabolite, MPP+, in the substantia nigra.
    • Understanding MPTP metabolism is crucial for comprehending its neurotoxic effects.

    More Related Videos

    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

    Published on: January 7, 2019

    The 6-hydroxydopamine Rat Model of Parkinson's Disease08:10

    The 6-hydroxydopamine Rat Model of Parkinson's Disease

    Published on: October 27, 2021

    Related Concept Videos

    Anticholinesterase Agents: Poisoning and Treatment01:26

    Anticholinesterase Agents: Poisoning and Treatment

    Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
    Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
    Parkinson Disease ll: Pathophysiology01:24

    Parkinson Disease ll: Pathophysiology

    Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...